Grant: CIHR Fellowship
University of Toronto
$135,000.00
Systematic identification and validation of novel drug targets from the ubiquitin cascade for the treatment of Her2 amplified breast cancer
EF 2013-14
Résumé
Her2 is a cancer promoting protein that is over-active in ~25% of breast cancers. Despite therapies that target Her2, this type of breast cancer has a relatively poor prognosis as these tumours often develop resistance, necessitating the need for more effective treatment strategies. In an effort to increase the efficacy of cancer drugs, they are often combined in multi-drug regimens; in Her2 amplified breast cancer however, these strategies have only resulted in incremental advances. My project aims to identify new combination strategies by focusing on a family of proteins that show considerable promise for controlling the survival and proliferation of breast cancer cells, but are extremely underdeveloped as drug targets. This family of over 600 enzymes modifies other proteins with a tag called ubiquitin, and in doing so, alters the signaling properties of the ubiquitinated protein, and sometimes the survivability of the cancer cell. The design of my project entails systematically removing each enzyme in isolation from cell line models of Her2 amplification, then treating these modified cells with Her2 drugs. After measuring cell death and proliferation, we can then assess which removed enzymes increase the efficacy of Her2 inhibitors. A huge challenge in cancer therapeutics involves surmising whether inhibiting these candidates with drugs can mimic the complete removal of the enzyme, as this is not feasible for treating humans. Fortunately, our lab has developed new technologies to generate probes that inhibit candidates from the initial screen, and therefore test the druggability of these targets. The importance of my work is rooted in our efforts to identify and validate new drug targets, thereby directing the development of the next generation of targeted therapeutics and positively impacting treatment strategies for Her2 amplified breast cancer.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
301041
Name
Turowec Jacob P
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Systematic identification and validation of novel drug targets from the ubiquitin cascade for the treatment of Her2 amplified breast cancer
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Drug Target Discovery; Drug Target Validation; Her2+ Breast Cancer; Phage Display; Pooled Shrna Dropout Screen; Protein Ubiquitylation; Synthetic/Genetic Interactions; Ubiquitin Variants
Abstract
Her2 is a cancer promoting protein that is over-active in ~25% of breast cancers. Despite therapies that target Her2, this type of breast cancer has a relatively poor prognosis as these tumours often develop resistance, necessitating the need for more effective treatment strategies. In an effort to increase the efficacy of cancer drugs, they are often combined in multi-drug regimens; in Her2 amplified breast cancer however, these strategies have only resulted in incremental advances. My project aims to identify new combination strategies by focusing on a family of proteins that show considerable promise for controlling the survival and proliferation of breast cancer cells, but are extremely underdeveloped as drug targets. This family of over 600 enzymes modifies other proteins with a tag called ubiquitin, and in doing so, alters the signaling properties of the ubiquitinated protein, and sometimes the survivability of the cancer cell. The design of my project entails systematically removing each enzyme in isolation from cell line models of Her2 amplification, then treating these modified cells with Her2 drugs. After measuring cell death and proliferation, we can then assess which removed enzymes increase the efficacy of Her2 inhibitors. A huge challenge in cancer therapeutics involves surmising whether inhibiting these candidates with drugs can mimic the complete removal of the enzyme, as this is not feasible for treating humans. Fortunately, our lab has developed new technologies to generate probes that inhibit candidates from the initial screen, and therefore test the druggability of these targets. The importance of my work is rooted in our efforts to identify and validate new drug targets, thereby directing the development of the next generation of targeted therapeutics and positively impacting treatment strategies for Her2 amplified breast cancer.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Turowec, Jacob P
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~